Reviva Pharmaceuticals Holdings, Inc. (RVPH)
NASDAQ: RVPH · Real-Time Price · USD
0.938
+0.005 (0.54%)
Nov 7, 2024, 11:31 AM EST - Market open
RVPH Employees
Reviva Pharmaceuticals Holdings had 15 employees as of December 31, 2023. The number of employees increased by 5 or 50.00% compared to the previous year.
Employees
15
Change (1Y)
5
Growth (1Y)
50.00%
Revenue / Employee
n/a
Profits / Employee
-$2,399,648
Market Cap
31.37M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 15 | 5 | 50.00% |
| Dec 31, 2022 | 10 | 5 | 100.00% |
| Dec 31, 2021 | 5 | 0 | - |
| Dec 31, 2020 | 5 | 1 | 25.00% |
| Dec 31, 2019 | 4 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| FibroGen | 486 |
| DarioHealth | 294 |
| Celularity | 120 |
| Longeveron | 24 |
| Lipocine | 17 |
| Ocean Biomedical | 9 |
| Dyadic International | 7 |
| Nexalin Technology | 6 |
RVPH News
- 1 day ago - Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024 - GlobeNewsWire
- 7 days ago - Reviva to Participate in the UBS Global Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit - GlobeNewsWire
- 5 weeks ago - Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference - GlobeNewsWire
- 2 months ago - Reviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
- 4 months ago - Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension - GlobeNewsWire
- 5 months ago - Reviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
- 5 months ago - Reviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire